APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuromyelitis Optica Drug

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Selected research

Market Analysis & Forecast

Global Neuromyelitis Optica Drug Market Analysis and Forecast 2026-2032

9 January 2026198 pages

Choose your research edition.

Industry ResearchNeuromyelitis Optica Drug Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuromyelitis Optica Drug Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Neuromyelitis Optica Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuromyelitis Optica Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuromyelitis Optica Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that aren't yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.

Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.

Europe is the largest Neuromyelitis Optica Drug market with about 40% market share. North America is follower, accounting for about 35% market share.

Read the full market overview

The key players are Pfizer, Fresenius, Teva, Sandoz, Intas, Gyjtrs, NANG KUANG, Tianjin Kingyork, Baxter, CSL, Grifols, Octapharma, CBOP etc. Top 3 companies occupied about 35% market share.

Report Includes

This report presents an overview of global market for Neuromyelitis Optica Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuromyelitis Optica Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Neuromyelitis Optica Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuromyelitis Optica Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuromyelitis Optica Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neuromyelitis Optica Drug revenue, projected growth trends, production technology, application and end-user industry.

Neuromyelitis Optica Drug Segment by Company

Pfizer

Fresenius

Teva

Sandoz

Intas

Gyjtrs

NANG KUANG

Tianjin Kingyork

Baxter

CSL

Grifols

Octapharma

CBOP

Neuromyelitis Optica Drug Segment by Type

Glucocorticoids

Immunotherapies

Others

Neuromyelitis Optica Drug Segment by Application

Acute Attack

Remission Prophylactic Treatment

Neuromyelitis Optica Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuromyelitis Optica Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuromyelitis Optica Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuromyelitis Optica Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neuromyelitis Optica Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neuromyelitis Optica Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuromyelitis Optica Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Glucocorticoids Major Player Table 3. Immunotherapies Major Player Table 4. Others Major Player Table 5. Global Neuromyelitis Optica Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Acute Attack Major Player Table 7. Remission Prophylactic Treatment Major Player Table 8. Neuromyelitis Optica Drug Industry Trends Table 9. Neuromyelitis Optica Drug Industry Drivers Table 10. Neuromyelitis Optica Drug Industry Opportunities and Challenges Table 11. Neuromyelitis Optica Drug Industry Restraints Table 12. Global Neuromyelitis Optica Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Neuromyelitis Optica Drug Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Neuromyelitis Optica Drug Market Share by Region (2021-2026) Table 15. Global Neuromyelitis Optica Drug Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Neuromyelitis Optica Drug Market Share by Region (2027-2032) Table 17. Global Neuromyelitis Optica Drug Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Neuromyelitis Optica Drug Revenue Market Share by Players (2021-2026) Table 19. Global Neuromyelitis Optica Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Neuromyelitis Optica Drug Key Players Headquarters & Area Served Table 21. Global Neuromyelitis Optica Drug Players, Product Type & Application Table 22. Global Neuromyelitis Optica Drug Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Neuromyelitis Optica Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Neuromyelitis Optica Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Neuromyelitis Optica Drug Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Neuromyelitis Optica Drug Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2021-2026) Table 29. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2027-2032) Table 30. Global Neuromyelitis Optica Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Neuromyelitis Optica Drug Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Neuromyelitis Optica Drug Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2021-2026) Table 34. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2027-2032) Table 35. Pfizer Company Information Table 36. Pfizer Business Overview Table 37. Pfizer Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Pfizer Neuromyelitis Optica Drug Product Portfolio Table 39. Pfizer Recent Development Table 40. Fresenius Company Information Table 41. Fresenius Business Overview Table 42. Fresenius Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Fresenius Neuromyelitis Optica Drug Product Portfolio Table 44. Fresenius Recent Development Table 45. Teva Company Information Table 46. Teva Business Overview Table 47. Teva Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Teva Neuromyelitis Optica Drug Product Portfolio Table 49. Teva Recent Development Table 50. Sandoz Company Information Table 51. Sandoz Business Overview Table 52. Sandoz Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Sandoz Neuromyelitis Optica Drug Product Portfolio Table 54. Sandoz Recent Development Table 55. Intas Company Information Table 56. Intas Business Overview Table 57. Intas Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Intas Neuromyelitis Optica Drug Product Portfolio Table 59. Intas Recent Development Table 60. Gyjtrs Company Information Table 61. Gyjtrs Business Overview Table 62. Gyjtrs Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Gyjtrs Neuromyelitis Optica Drug Product Portfolio Table 64. Gyjtrs Recent Development Table 65. NANG KUANG Company Information Table 66. NANG KUANG Business Overview Table 67. NANG KUANG Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. NANG KUANG Neuromyelitis Optica Drug Product Portfolio Table 69. NANG KUANG Recent Development Table 70. Tianjin Kingyork Company Information Table 71. Tianjin Kingyork Business Overview Table 72. Tianjin Kingyork Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio Table 74. Tianjin Kingyork Recent Development Table 75. Baxter Company Information Table 76. Baxter Business Overview Table 77. Baxter Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Baxter Neuromyelitis Optica Drug Product Portfolio Table 79. Baxter Recent Development Table 80. CSL Company Information Table 81. CSL Business Overview Table 82. CSL Neuromyelitis Optica Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. CSL Neuromyelitis Optica Drug Product Portfolio Table 84. CSL Recent Development Table 85. Grifols Company Information Table 86. Grifols Business Overview Table 87. Grifols Neuromyelitis Optica Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 88. Grifols Neuromyelitis Optica Drug Product Portfolio Table 89. Grifols Recent Development Table 90. Octapharma Company Information Table 91. Octapharma Business Overview Table 92. Octapharma Neuromyelitis Optica Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 93. Octapharma Neuromyelitis Optica Drug Product Portfolio Table 94. Octapharma Recent Development Table 95. CBOP Company Information Table 96. CBOP Business Overview Table 97. CBOP Neuromyelitis Optica Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 98. CBOP Neuromyelitis Optica Drug Product Portfolio Table 99. CBOP Recent Development Table 100. North America Neuromyelitis Optica Drug Revenue by Type (2021-2026) & (US$ Million) Table 101. North America Neuromyelitis Optica Drug Revenue by Type (2027-2032) & (US$ Million) Table 102. North America Neuromyelitis Optica Drug Revenue by Application (2021-2026) & (US$ Million) Table 103. North America Neuromyelitis Optica Drug Revenue by Application (2027-2032) & (US$ Million) Table 104. North America Neuromyelitis Optica Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 105. North America Neuromyelitis Optica Drug Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Neuromyelitis Optica Drug Revenue by Country (US$ Million) & (2027-2032) Table 107. Europe Neuromyelitis Optica Drug Revenue by Type (2021-2026) & (US$ Million) Table 108. Europe Neuromyelitis Optica Drug Revenue by Type (2027-2032) & (US$ Million) Table 109. Europe Neuromyelitis Optica Drug Revenue by Application (2021-2026) & (US$ Million) Table 110. Europe Neuromyelitis Optica Drug Revenue by Application (2027-2032) & (US$ Million) Table 111. Europe Neuromyelitis Optica Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Europe Neuromyelitis Optica Drug Revenue by Country (2021-2026) & (US$ Million) Table 113. Europe Neuromyelitis Optica Drug Revenue by Country (US$ Million) & (2027-2032) Table 114. China Neuromyelitis Optica Drug Revenue by Type (2021-2026) & (US$ Million) Table 115. China Neuromyelitis Optica Drug Revenue by Type (2027-2032) & (US$ Million) Table 116. China Neuromyelitis Optica Drug Revenue by Application (2021-2026) & (US$ Million) Table 117. China Neuromyelitis Optica Drug Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Neuromyelitis Optica Drug Revenue by Type (2021-2026) & (US$ Million) Table 119. Asia Neuromyelitis Optica Drug Revenue by Type (2027-2032) & (US$ Million) Table 120. Asia Neuromyelitis Optica Drug Revenue by Application (2021-2026) & (US$ Million) Table 121. Asia Neuromyelitis Optica Drug Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia Neuromyelitis Optica Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Asia Neuromyelitis Optica Drug Revenue by Region (US$ Million) & (2021-2026) Table 124. Asia Neuromyelitis Optica Drug Revenue by Region (US$ Million) & (2027-2032) Table 125. SAMEA Neuromyelitis Optica Drug Revenue by Type (2021-2026) & (US$ Million) Table 126. SAMEA Neuromyelitis Optica Drug Revenue by Type (2027-2032) & (US$ Million) Table 127. SAMEA Neuromyelitis Optica Drug Revenue by Application (2021-2026) & (US$ Million) Table 128. SAMEA Neuromyelitis Optica Drug Revenue by Application (2027-2032) & (US$ Million) Table 129. SAMEA Neuromyelitis Optica Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. SAMEA Neuromyelitis Optica Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. SAMEA Neuromyelitis Optica Drug Revenue by Country (US$ Million) & (2027-2032) Table 132. Research Programs/Design for This Report Table 133. Authors List of This Report Table 134. Secondary Sources Table 135. Primary Sources List of Figures Figure 1. Neuromyelitis Optica Drug Image Figure 2. Global Neuromyelitis Optica Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuromyelitis Optica Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Glucocorticoids Image Figure 5. Immunotherapies Image Figure 6. Others Image Figure 7. Global Neuromyelitis Optica Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Neuromyelitis Optica Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. Acute Attack Image Figure 10. Remission Prophylactic Treatment Image Figure 11. Global Neuromyelitis Optica Drug Market Size (US$ Million) & (2021-2032) Figure 12. Global Neuromyelitis Optica Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Neuromyelitis Optica Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Neuromyelitis Optica Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Neuromyelitis Optica Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neuromyelitis Optica Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Neuromyelitis Optica Drug Revenue Market Share by Type (2021-2032) Figure 19. Global Neuromyelitis Optica Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Neuromyelitis Optica Drug Revenue Market Share by Application (2021-2032) Figure 22. North America Neuromyelitis Optica Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Neuromyelitis Optica Drug Revenue Share by Type (2021-2032) Figure 24. North America Neuromyelitis Optica Drug Revenue Share by Application (2021-2032) Figure 25. North America Neuromyelitis Optica Drug Revenue Share by Country (2021-2032) Figure 26. United States Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Neuromyelitis Optica Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Neuromyelitis Optica Drug Revenue Share by Type (2021-2032) Figure 31. Europe Neuromyelitis Optica Drug Revenue Share by Application (2021-2032) Figure 32. Europe Neuromyelitis Optica Drug Revenue Share by Country (2021-2032) Figure 33. Germany Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Neuromyelitis Optica Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Neuromyelitis Optica Drug Revenue Share by Type (2021-2032) Figure 43. China Neuromyelitis Optica Drug Revenue Share by Application (2021-2032) Figure 44. Asia Neuromyelitis Optica Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Neuromyelitis Optica Drug Revenue Share by Type (2021-2032) Figure 46. Asia Neuromyelitis Optica Drug Revenue Share by Application (2021-2032) Figure 47. Asia Neuromyelitis Optica Drug Revenue Share by Region (2021-2032) Figure 48. Japan Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Neuromyelitis Optica Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Neuromyelitis Optica Drug Revenue Share by Type (2021-2032) Figure 56. SAMEA Neuromyelitis Optica Drug Revenue Share by Application (2021-2032) Figure 57. SAMEA Neuromyelitis Optica Drug Revenue Share by Country (2021-2032) Figure 58. Brazil Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Neuromyelitis Optica Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Glucocorticoids
  • Immunotherapies
  • Others
Applications
  • Acute Attack
  • Remission Prophylactic Treatment
Companies covered
  • Pfizer
  • Fresenius
  • Teva
  • Sandoz
  • Intas
  • Gyjtrs
  • NANG KUANG
  • Tianjin Kingyork
  • Baxter
  • CSL
  • Grifols
  • Octapharma
  • CBOP

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuromyelitis Optica Drug Market by Type
  3. 1.2.1 Global Neuromyelitis Optica Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Glucocorticoids
  5. 1.2.3 Immunotherapies
  6. 1.2.4 Others
  7. 1.3 Neuromyelitis Optica Drug Market by Application
  8. 1.3.1 Global Neuromyelitis Optica Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Acute Attack
  10. 1.3.3 Remission Prophylactic Treatment
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Neuromyelitis Optica Drug Market Dynamics
  1. 2.1 Neuromyelitis Optica Drug Industry Trends
  2. 2.2 Neuromyelitis Optica Drug Industry Drivers
  3. 2.3 Neuromyelitis Optica Drug Industry Opportunities and Challenges
  4. 2.4 Neuromyelitis Optica Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neuromyelitis Optica Drug Market Perspective (2021-2032)
  2. 3.2 Global Neuromyelitis Optica Drug Growth Trends by Region
  3. 3.2.1 Global Neuromyelitis Optica Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuromyelitis Optica Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Neuromyelitis Optica Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neuromyelitis Optica Drug Revenue by Players
  2. 4.1.1 Global Neuromyelitis Optica Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Neuromyelitis Optica Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neuromyelitis Optica Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuromyelitis Optica Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neuromyelitis Optica Drug Key Players Headquarters & Area Served
  7. 4.4 Global Neuromyelitis Optica Drug Players, Product Type & Application
  8. 4.5 Global Neuromyelitis Optica Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neuromyelitis Optica Drug Market CR5 and HHI
  11. 4.6.3 2025 Neuromyelitis Optica Drug Tier 1, Tier 2, and Tier 3
5 Neuromyelitis Optica Drug Market Size by Type
  1. 5.1 Global Neuromyelitis Optica Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuromyelitis Optica Drug Revenue by Type (2021-2032)
  3. 5.3 Global Neuromyelitis Optica Drug Revenue Market Share by Type (2021-2032)
6 Neuromyelitis Optica Drug Market Size by Application
  1. 6.1 Global Neuromyelitis Optica Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neuromyelitis Optica Drug Revenue by Application (2021-2032)
  3. 6.3 Global Neuromyelitis Optica Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Neuromyelitis Optica Drug Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 Fresenius
  8. 7.2.1 Fresenius Company Information
  9. 7.2.2 Fresenius Business Overview
  10. 7.2.3 Fresenius Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Fresenius Neuromyelitis Optica Drug Product Portfolio
  12. 7.2.5 Fresenius Recent Developments
  13. 7.3 Teva
  14. 7.3.1 Teva Company Information
  15. 7.3.2 Teva Business Overview
  16. 7.3.3 Teva Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Teva Neuromyelitis Optica Drug Product Portfolio
  18. 7.3.5 Teva Recent Developments
  19. 7.4 Sandoz
  20. 7.4.1 Sandoz Company Information
  21. 7.4.2 Sandoz Business Overview
  22. 7.4.3 Sandoz Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sandoz Neuromyelitis Optica Drug Product Portfolio
  24. 7.4.5 Sandoz Recent Developments
  25. 7.5 Intas
  26. 7.5.1 Intas Company Information
  27. 7.5.2 Intas Business Overview
  28. 7.5.3 Intas Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Intas Neuromyelitis Optica Drug Product Portfolio
  30. 7.5.5 Intas Recent Developments
  31. 7.6 Gyjtrs
  32. 7.6.1 Gyjtrs Company Information
  33. 7.6.2 Gyjtrs Business Overview
  34. 7.6.3 Gyjtrs Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Gyjtrs Neuromyelitis Optica Drug Product Portfolio
  36. 7.6.5 Gyjtrs Recent Developments
  37. 7.7 NANG KUANG
  38. 7.7.1 NANG KUANG Company Information
  39. 7.7.2 NANG KUANG Business Overview
  40. 7.7.3 NANG KUANG Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 NANG KUANG Neuromyelitis Optica Drug Product Portfolio
  42. 7.7.5 NANG KUANG Recent Developments
  43. 7.8 Tianjin Kingyork
  44. 7.8.1 Tianjin Kingyork Company Information
  45. 7.8.2 Tianjin Kingyork Business Overview
  46. 7.8.3 Tianjin Kingyork Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Tianjin Kingyork Neuromyelitis Optica Drug Product Portfolio
  48. 7.8.5 Tianjin Kingyork Recent Developments
  49. 7.9 Baxter
  50. 7.9.1 Baxter Company Information
  51. 7.9.2 Baxter Business Overview
  52. 7.9.3 Baxter Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Baxter Neuromyelitis Optica Drug Product Portfolio
  54. 7.9.5 Baxter Recent Developments
  55. 7.10 CSL
  56. 7.10.1 CSL Company Information
  57. 7.10.2 CSL Business Overview
  58. 7.10.3 CSL Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 CSL Neuromyelitis Optica Drug Product Portfolio
  60. 7.10.5 CSL Recent Developments
  61. 7.11 Grifols
  62. 7.11.1 Grifols Company Information
  63. 7.11.2 Grifols Business Overview
  64. 7.11.3 Grifols Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Grifols Neuromyelitis Optica Drug Product Portfolio
  66. 7.11.5 Grifols Recent Developments
  67. 7.12 Octapharma
  68. 7.12.1 Octapharma Company Information
  69. 7.12.2 Octapharma Business Overview
  70. 7.12.3 Octapharma Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Octapharma Neuromyelitis Optica Drug Product Portfolio
  72. 7.12.5 Octapharma Recent Developments
  73. 7.13 CBOP
  74. 7.13.1 CBOP Company Information
  75. 7.13.2 CBOP Business Overview
  76. 7.13.3 CBOP Neuromyelitis Optica Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 CBOP Neuromyelitis Optica Drug Product Portfolio
  78. 7.13.5 CBOP Recent Developments
8 North America
  1. 8.1 North America Neuromyelitis Optica Drug Revenue (2021-2032)
  2. 8.2 North America Neuromyelitis Optica Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Neuromyelitis Optica Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Neuromyelitis Optica Drug Revenue by Type (2027-2032)
  5. 8.3 North America Neuromyelitis Optica Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Neuromyelitis Optica Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Neuromyelitis Optica Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Neuromyelitis Optica Drug Revenue by Application (2027-2032)
  9. 8.5 North America Neuromyelitis Optica Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Neuromyelitis Optica Drug Revenue by Country
  11. 8.6.1 North America Neuromyelitis Optica Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neuromyelitis Optica Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Neuromyelitis Optica Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Neuromyelitis Optica Drug Revenue (2021-2032)
  2. 9.2 Europe Neuromyelitis Optica Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neuromyelitis Optica Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neuromyelitis Optica Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Neuromyelitis Optica Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neuromyelitis Optica Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neuromyelitis Optica Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neuromyelitis Optica Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Neuromyelitis Optica Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neuromyelitis Optica Drug Revenue by Country
  11. 9.6.1 Europe Neuromyelitis Optica Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neuromyelitis Optica Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neuromyelitis Optica Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Neuromyelitis Optica Drug Revenue (2021-2032)
  2. 10.2 China Neuromyelitis Optica Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Neuromyelitis Optica Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Neuromyelitis Optica Drug Revenue by Type (2027-2032)
  5. 10.3 China Neuromyelitis Optica Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Neuromyelitis Optica Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Neuromyelitis Optica Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Neuromyelitis Optica Drug Revenue by Application (2027-2032)
  9. 10.5 China Neuromyelitis Optica Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuromyelitis Optica Drug Revenue (2021-2032)
  2. 11.2 Asia Neuromyelitis Optica Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neuromyelitis Optica Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neuromyelitis Optica Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Neuromyelitis Optica Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neuromyelitis Optica Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neuromyelitis Optica Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neuromyelitis Optica Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Neuromyelitis Optica Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neuromyelitis Optica Drug Revenue by Country
  11. 11.6.1 Asia Neuromyelitis Optica Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neuromyelitis Optica Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neuromyelitis Optica Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuromyelitis Optica Drug Revenue (2021-2032)
  2. 12.2 SAMEA Neuromyelitis Optica Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neuromyelitis Optica Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neuromyelitis Optica Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neuromyelitis Optica Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neuromyelitis Optica Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neuromyelitis Optica Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neuromyelitis Optica Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neuromyelitis Optica Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neuromyelitis Optica Drug Revenue by Country
  11. 12.6.1 SAMEA Neuromyelitis Optica Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neuromyelitis Optica Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neuromyelitis Optica Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst